Skip to main content
. 2020 Jul 30;7(5):e837. doi: 10.1212/NXI.0000000000000837

Figure 2. The efficacy of various disease-modifying therapies in children with AQP4-Ab NMOSD.

Figure 2

Annualized relapse rates (ARRs) before and after treatment initiation with the most frequently used medications. (A) Azathioprine (AZA). (B) Mycophenolate mofetil (MMF). (C) Rituximab. (D) After escalation from treatment with AZA or MMF to rituximab.